Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
AMSTERDAM, July 18, 2012 /PRNewswire/ –
Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced that it is pleased to have
the opportunity to participate in SCOAP3 [http://scoap3.org/about.html ] (Sponsoring
Consortium for Open Access Publishing in Particle Physics), a new model for open access
publishing. Key SCOAP3 principles [http://scoap3.org/files/Technical_Specification.pdf ]
are perpetual open access, wide re-use licenses, and reduction and re-direction of
subscription fees to centrally cover for article processing charges in journals carrying
SCOAP3 content, with no charges to authors.
“After many years of intense preparations, we are excited to be a part of this
important initiative,” said Charon Duermeijer, Publishing Director and head of Elsevier’s
Physics journals. “Elsevier is looking forward to a close, fruitful and long-lasting
collaboration with SCOAP3 and the High Energy Physics community.”
Under SCOAP3 two well-established Elsevier journals — Physics LettersB
[http://www.journals.elsevier.com/physics-letters-b ] and Nuclear PhysicsB
[http://www.journals.elsevier.com/nuclear-physics-b ] — will change from a subscription
based model into an open access model by the start of 2014. Both journals are fully
focused on publications from the High Energy Physics field. Articles funded by SCOAP3 will
be available open access in perpetuity, under a CC-BY license.
“SCOAP3 is pleased that Physics Letters B and Nuclear Physics B participate in this
initiative, as these journals have played since long an important role in High-Energy
Physics literature,” said Salvatore Mele, SCOAP3 project manager at CERN.
Acting for the benefit of SCOAP3, CERN conducted the tendering. This open and
competitive procedure took into account the quality of journals (as measured by Impact
Factor), the quality of services provided (as measured by re-use licenses and delivery
formats), and the unit price for publishing each article.
See the official SCOAP3 announcement here [http://scoap3.org/news/news94.html ].
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Mosby’s Nursing Suite [http://www.confidenceconnected.com
], which enhance the productivity of science and health professionals, and the SciVal
suite [http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which
help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC
[http://www.reedelsevier.com ], a world-leading publisher and information provider, which
is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN
(Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
Media contact Tom Reller Vice President, Global Corporate Relations, Elsevier +1-215-239-3508 t.reller@Elsevier.com